Brian Albertson, MD
Sports Medicine · Corydon, INNPI 1023173077
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 52 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations.
Across 52 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$116
- Novo Nordisk$100
- GSK$95
- AbbVie$88
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$86
- Boston Scientific$81
- plus $349 from 12 others
What the payments were for
- Food & beverage$915100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 8 | $116 |
| Novo Nordisk | 7 | $100 |
| GSK | 6 | $95 |
| AbbVie(2 entities) | 5 | $88 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $86 |
| Boston Scientific | 1 | $81 |
| Otsuka America Pharmaceutical, Inc. | 5 | $80 |
| Medtronic | 2 | $49 |
| Lilly USA, LLC | 2 | $44 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Eisai Inc. | 2 | $29 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Sunovion Pharmaceuticals Inc. | 1 | $13 |
How this compares
$915 in reported general payments places this provider in the 60th percentile of 156 sports medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 89 | $106,327 |
| OzempicSemaglutide | 62 | $99,504 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $60,147 |
| JardianceEmpagliflozin | 55 | $54,142 |
| CaplytaLumateperone Tosylate | 26 | $52,692 |
| EliquisApixaban | 59 | $50,916 |
| Xtampza ErOxycodone Myristate | 18 | $37,852 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 44 | $34,854 |
| FarxigaDapagliflozin Propanediol | 43 | $24,309 |
| JanuviaSitagliptin Phosphate | 12 | $19,534 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $18,183 |
| RexultiBrexpiprazole | 12 | $17,375 |
| XareltoRivaroxaban | 12 | $16,521 |
| MovantikNaloxegol Oxalate | 38 | $15,553 |
| OxycontinOxycodone Hcl | 14 | $15,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Humulin 70-30 | $44 | $109,871126 claims |
| Novo NordiskOzempic | $100 | $99,50462 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $95 | $64,98387 claims |
| AstraZenecaBreztri Aerosphere, Farxiga, Symbicort | $116 | $62,728102 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $22 | $52,69226 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $80 | $17,37512 claims |
| Astellas Pharma US IncMyrbetriq | $19 | $12,07811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 156 sports medicine providers in Indiana.
Other sports medicine in Corydon
- Jorge ChahlaMunster$917K
- Sean CallowayGreenwood$130K
- Ryan NixonGreenwood$62K
- Tyler McCarrollCarmel$60K
- Nedal AlkhatibIndianapolis$51K
- Stephen ShivelyGreenfield$51K
- Dale SneadCarmel$45K
- Gregory FoxBloomington$37K
- Gregory WynneNoblesville$36K
- Brian WisselLawrenceburg$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.